S Patil

Summary

Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA

Publications

  1. doi request reprint Improvement in overall survival of patients with advanced renal cell carcinoma: prognostic factor trend analysis from an international data set of clinical trials
    Sujata Patil
    Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    J Urol 188:2095-100. 2012
  2. pmc Q-TWiST analysis to estimate overall benefit for patients with metastatic renal cell carcinoma treated in a phase III trial of sunitinib vs interferon-α
    S Patil
    Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Br J Cancer 106:1587-90. 2012
  3. doi request reprint Prognostic factors for progression-free and overall survival with sunitinib targeted therapy and with cytokine as first-line therapy in patients with metastatic renal cell carcinoma
    S Patil
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Ann Oncol 22:295-300. 2011
  4. ncbi request reprint Paclitaxel (T) plus ifosfamide (I) followed by high-dose carboplatin (C) and etoposide (E) with autologous stem cell support for patients (pts) with previously treated germ cell tumors (GCT): TI-CE results and prognostic factor analysis in 107 pts
    D R Feldman
    Memorial Sloan Kettering Cancer Center, New York, NY
    J Clin Oncol 27:5027. 2009
  5. ncbi request reprint Prognostic factors for overall survival with sunitinib as first-line therapy in patients with metastatic renal cell carcinoma (mRCC)
    S Patil
    Memorial Sloan Kettering Cancer Center, New York, NY City of Hope Comprehensive Cancer Center, Duarte, CA Baylor Sammons Cancer Center Texas Oncology, PA, Dallas, TX Massachusetts General Hospital Cancer Center, Boston, MA Centre Léon Bérard, Lyon, France Pfizer Oncology, La Jolla, CA
    J Clin Oncol 27:5042. 2009
  6. ncbi request reprint Hypoxia-inducible factor (HIF) 1α and 2α levels in cell lines and human tumor predicts response to sunitinib in renal cell carcinoma (RCC)
    P H Patel
    Memorial Sloan Kettering Cancer Center, New York, NY
    J Clin Oncol 26:5008. 2008
  7. ncbi request reprint Outcome prediction in adult male germ cell tumor patients through expression profiling
    J Korkola
    Sloan Kettering Institute for Cancer Research, New York, NY Memorial Sloan Kettering Cancer Center, New York, NY
    J Clin Oncol 26:5084. 2008
  8. ncbi request reprint Treatment outcome and survival for patients (pts) with sarcomatoid-variant metastatic renal cell carcinoma (RCC): Memorial Sloan-Kettering Cancer Center (MSKCC) experience
    A M Molina
    Memorial Sloan Kettering Cancer Center, New York, NY
    J Clin Oncol 27:e16017. 2009
  9. ncbi request reprint Phase I trial of RAD001 (everolimus) plus sunitinib in patients with metastatic renal cell carcinoma
    G S Kroog
    Memorial Sloan Kettering Cancer Center, New York, NY Crystal Run Healthcare, Middletown, NY
    J Clin Oncol 27:5037. 2009
  10. ncbi request reprint Phase I trial sunitinib plus everolimus in patients with metastatic renal cell carcinoma (mRCC)
    A M Molina
    Memorial Sloan Kettering Cancer Center, New York, NY
    J Clin Oncol 29:311. 2011

Collaborators

Detail Information

Publications15

  1. doi request reprint Improvement in overall survival of patients with advanced renal cell carcinoma: prognostic factor trend analysis from an international data set of clinical trials
    Sujata Patil
    Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    J Urol 188:2095-100. 2012
    ..We assessed temporal shifts in the frequency of risk factors for patients with metastatic renal cell carcinoma in a multicenter, international data set...
  2. pmc Q-TWiST analysis to estimate overall benefit for patients with metastatic renal cell carcinoma treated in a phase III trial of sunitinib vs interferon-α
    S Patil
    Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Br J Cancer 106:1587-90. 2012
    ..We assessed between-treatment differences in overall benefit using a quality-adjusted Time Without Symptoms of disease progression or Toxicity of treatment (TWiST; Gelber and Goldhirsch) analysis...
  3. doi request reprint Prognostic factors for progression-free and overall survival with sunitinib targeted therapy and with cytokine as first-line therapy in patients with metastatic renal cell carcinoma
    S Patil
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Ann Oncol 22:295-300. 2011
    ....
  4. ncbi request reprint Paclitaxel (T) plus ifosfamide (I) followed by high-dose carboplatin (C) and etoposide (E) with autologous stem cell support for patients (pts) with previously treated germ cell tumors (GCT): TI-CE results and prognostic factor analysis in 107 pts
    D R Feldman
    Memorial Sloan Kettering Cancer Center, New York, NY
    J Clin Oncol 27:5027. 2009
    ..67:1305). The doses, schedule, and safety of TI-CE in this population were previously reported (J Clin Oncol. 25: 85). Efficacy and prognostic factor analysis are now presented...
  5. ncbi request reprint Prognostic factors for overall survival with sunitinib as first-line therapy in patients with metastatic renal cell carcinoma (mRCC)
    S Patil
    Memorial Sloan Kettering Cancer Center, New York, NY City of Hope Comprehensive Cancer Center, Duarte, CA Baylor Sammons Cancer Center Texas Oncology, PA, Dallas, TX Massachusetts General Hospital Cancer Center, Boston, MA Centre Léon Bérard, Lyon, France Pfizer Oncology, La Jolla, CA
    J Clin Oncol 27:5042. 2009
    ..4 vs. 21.8 months (HR=0.821; P=0.051 by unstratified log-rank test; Proc ASCO 2008;26, May 20 suppl; abstr 5024). An analysis of prognostic factors for OS was performed on data from this trial...
  6. ncbi request reprint Hypoxia-inducible factor (HIF) 1α and 2α levels in cell lines and human tumor predicts response to sunitinib in renal cell carcinoma (RCC)
    P H Patel
    Memorial Sloan Kettering Cancer Center, New York, NY
    J Clin Oncol 26:5008. 2008
    ..HIF1α and HIF2α actions underlie progression of RCC; and their relationship to clinical response warrants study...
  7. ncbi request reprint Outcome prediction in adult male germ cell tumor patients through expression profiling
    J Korkola
    Sloan Kettering Institute for Cancer Research, New York, NY Memorial Sloan Kettering Cancer Center, New York, NY
    J Clin Oncol 26:5084. 2008
    ..Currently, patients are risk-stratified using clinical markers defined by the International Germ Cell Cancer Consensus Group (IGCCCG). Identification of molecular markers could improve outcome prediction...
  8. ncbi request reprint Treatment outcome and survival for patients (pts) with sarcomatoid-variant metastatic renal cell carcinoma (RCC): Memorial Sloan-Kettering Cancer Center (MSKCC) experience
    A M Molina
    Memorial Sloan Kettering Cancer Center, New York, NY
    J Clin Oncol 27:e16017. 2009
    ..MSKCC experience was studied to provide data on outcome and survival to systemic therapy for metastatic, sarcomatoid-variant RCC...
  9. ncbi request reprint Phase I trial of RAD001 (everolimus) plus sunitinib in patients with metastatic renal cell carcinoma
    G S Kroog
    Memorial Sloan Kettering Cancer Center, New York, NY Crystal Run Healthcare, Middletown, NY
    J Clin Oncol 27:5037. 2009
    ..Combining RAD001 and sunitinib may increase antitumor efficacy by maximizing inhibition of HIF-dependent signaling. The safety and maximum tolerated dose (MTD) of sunitinib in combination with RAD001 was assessed in this phase I trial...
  10. ncbi request reprint Phase I trial sunitinib plus everolimus in patients with metastatic renal cell carcinoma (mRCC)
    A M Molina
    Memorial Sloan Kettering Cancer Center, New York, NY
    J Clin Oncol 29:311. 2011
    ..The safety and maximum tolerated dose (MTD) of sunitinib in combination with everolimus was assessed in this phase I trial...
  11. ncbi request reprint Long-term response to sunitinib for metastatic renal cell carcinoma (mRCC) patients treated on clinical trials at Memorial Sloan-Kettering Cancer Center
    A M Molina
    Memorial Sloan Kettering Cancer Center, New York, NY
    J Clin Oncol 29:4615. 2011
    ..4615 Background: Sunitinib has significant activity in pts with mRCC. We report long-term responders, defined as pts achieving ongoing complete response (CR) or remaining progression-free for > 18 months on sunitinib...
  12. ncbi request reprint Trends in Memorial Sloan-Kettering Cancer Center risk group distribution according to treatment year for patients with metastatic renal cell carcinoma (mRCC)
    S Patil
    Memorial Sloan Kettering Cancer Center, New York, NY
    J Clin Oncol 26:5092. 2008
    ..17, 2530-2540). Risk group frequencies were examined by year of treatment at MSKCC to assess trends...
  13. ncbi request reprint Clinical features of germ cell tumors (GCT) in men age 50 or older: Successful outcome and tolerability to chemotherapy for advanced disease
    M H Voss
    Memorial Sloan Kettering Cancer Center, New York, NY
    J Clin Oncol 29:4656. 2011
    ..4656 Background: Most patients with GCT are diagnosed and treated below age 50. For patients ≥50, less is known about possible differences in biology, outcome and tolerability of treatment...
  14. ncbi request reprint Risk factor migration and survival: Analysis from international dataset of 3,748 metastatic renal cell carcinoma (mRCC) patients treated on clinical trials
    S Patil
    Memorial Sloan Kettering Cancer Center, New York, NY Dana Farber Cancer Institute, Boston, MA Cleveland Clinic, Cleveland, OH Kidney Cancer Association, Evanston, IL University Lyon, Lyon, France Institut Gustave Roussy, Villejuif, France Cleveland Clinic Taussig Cancer Institute, Cleveland, OH
    J Clin Oncol 29:4554. 2011
    ..This analysis aims to investigate shifts in the frequency of known risk factors for mRCC patients in a multicenter, international experience of patient data collected to examine prognostic factors (Clin Cancer Res. 10[18 Pt 2])...
  15. ncbi request reprint Molecular classification of sunitinib response in metastatic renal cell carcinoma (mRCC) patients by gene expression profiling
    V J Thodima
    Memorial Sloan Kettering Cancer Center, New York, NY
    J Clin Oncol 29:4556. 2011
    ..Identification of molecular markers could improve outcome prediction and improve our understanding of mechanisms of resistance...